Optimal testing strategies for incidental anti-mitochondrial M2 antibody-positive patients

Abstract

We carefully considered the letter entitled “Optimal testing strategies for incidental anti-mitochondrial M2 antibody-positive patients.” We sincerely appreciate the authors’ insights and the thoughtful review of our paper, “The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients”.[1,2] We wish to offer clarification on the issues raised in the letter.